208 related articles for article (PubMed ID: 35076789)
1. Mycobacterium bovis bacille Calmette-Guerin-derived extracellular vesicles as an alternative to live BCG immunotherapy.
Gellings P; Galeas-Pena M; Morici LA
Clin Exp Med; 2023 Jun; 23(2):519-527. PubMed ID: 35076789
[TBL] [Abstract][Full Text] [Related]
2. Killed but metabolically active Mycobacterium bovis bacillus Calmette-Guérin retains the antitumor ability of live bacillus Calmette-Guérin.
Secanella-Fandos S; Noguera-Ortega E; Olivares F; Luquin M; Julián E
J Urol; 2014 May; 191(5):1422-8. PubMed ID: 24333111
[TBL] [Abstract][Full Text] [Related]
3. A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14.
Rentsch CA; Thalmann GN; Lucca I; Kwiatkowski M; Wirth GJ; Strebel RT; Engeler D; Pedrazzini A; Hüttenbrink C; Schultze-Seemann W; Torpai R; Bubendorf L; Wicki A; Roth B; Bosshard P; Püschel H; Boll DT; Hefermehl L; Roghmann F; Gierth M; Ribi K; Schäfer S; Hayoz S
Eur Urol Oncol; 2022 Apr; 5(2):195-202. PubMed ID: 35012889
[TBL] [Abstract][Full Text] [Related]
4. Bacillus Calmette-Guérin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections.
Larsen ES; Joensen UN; Poulsen AM; Goletti D; Johansen IS
APMIS; 2020 Feb; 128(2):92-103. PubMed ID: 31755155
[TBL] [Abstract][Full Text] [Related]
5. A report of iliac muscle abscess due to Mycobacterium bovis after bacillus Calmette-Guerin therapy for bladder cancer.
Talluri SK; Marigowda L; Besur S; Talluri J; Forstall GJ
South Med J; 2010 Apr; 103(4):369-70. PubMed ID: 20224496
[TBL] [Abstract][Full Text] [Related]
6. Preoperative sarcopenia and systemic immune-inflammation index can predict response to intravesical Bacillus Calmette-Guerin instillation in patients with non-muscle invasive bladder cancer.
Liu P; Chen S; Gao X; Liang H; Sun D; Shi B; Zhang Q; Guo H
Front Immunol; 2022; 13():1032907. PubMed ID: 36225922
[TBL] [Abstract][Full Text] [Related]
7. Bacillus Calmette-Guérin strain differences as the basis for immunotherapies against bladder cancer.
Miyazaki J; Onozawa M; Takaoka E; Yano I
Int J Urol; 2018 May; 25(5):405-413. PubMed ID: 29506322
[TBL] [Abstract][Full Text] [Related]
8. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine.
Kawai K; Miyazaki J; Joraku A; Nishiyama H; Akaza H
Cancer Sci; 2013 Jan; 104(1):22-7. PubMed ID: 23181987
[TBL] [Abstract][Full Text] [Related]
9. Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer.
Begnini KR; Buss JH; Collares T; Seixas FK
Appl Microbiol Biotechnol; 2015 May; 99(9):3741-54. PubMed ID: 25794874
[TBL] [Abstract][Full Text] [Related]
10. Mycobacterium bovis osteomyelitis involving a hip arthroplasty after intravesicular bacille Calmette-Guérin for bladder cancer.
Guerra CE; Betts RF; O'Keefe RJ; Shilling JW
Clin Infect Dis; 1998 Sep; 27(3):639-40. PubMed ID: 9770167
[TBL] [Abstract][Full Text] [Related]
11. How Should I Manage a Patient with Tumor Recurrence Despite Adequate Bacille Calmette-Guérin?
Kamat AM; Gontero P; Palou J
Eur Urol Oncol; 2020 Apr; 3(2):252-257. PubMed ID: 31307960
[TBL] [Abstract][Full Text] [Related]
12. Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancer.
Simons MP; Nauseef WM; Griffith TS
Immunol Res; 2007; 39(1-3):79-93. PubMed ID: 17917057
[TBL] [Abstract][Full Text] [Related]
13. Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder.
Kresowik TP; Griffith TS
Immunotherapy; 2009 Mar; 1(2):281-8. PubMed ID: 20046960
[TBL] [Abstract][Full Text] [Related]
14. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
[TBL] [Abstract][Full Text] [Related]
15. Bacille Calmette-Guérin vaccine.
Wittes RC
Clin Infect Dis; 2000 Sep; 31 Suppl 3():S115-21. PubMed ID: 11010836
[No Abstract] [Full Text] [Related]
16. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
[TBL] [Abstract][Full Text] [Related]
17. Selective delipidation of Mycobacterium bovis BCG retains antitumor efficacy against non-muscle invasive bladder cancer.
Ji N; Long M; Garcia-Vilanova A; Ault R; Moliva JI; Yusoof KA; Mukherjee N; Curiel TJ; Dixon H; Torrelles JB; Svatek RS
Cancer Immunol Immunother; 2023 Jan; 72(1):125-136. PubMed ID: 35748904
[TBL] [Abstract][Full Text] [Related]
18. Aortic aneurysm and aortic graft infection related to Mycobacterium bovis after intravesical Bacille Calmette-Guérin therapy-a case series.
Buerger M; Kapahnke S; Omran S; Schomaker M; Rief M; Greiner A; Frese JP
BMC Surg; 2021 Mar; 21(1):138. PubMed ID: 33731071
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of recombinant Bacille Calmette-Guérin secreting interleukin-15-Ag85B fusion protein against bladder cancer.
Takeuchi A; Eto M; Tatsugami K; Shiota M; Yamada H; Kamiryo Y; Dejima T; Kashiwagi E; Kiyoshima K; Inokuchi J; Takahashi R; Yokomizo A; Ohara N; Yoshikai Y
Int Immunopharmacol; 2016 Jun; 35():327-331. PubMed ID: 27093372
[TBL] [Abstract][Full Text] [Related]
20. Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer.
Luo Y; Henning J; O'Donnell MA
Clin Dev Immunol; 2011; 2011():728930. PubMed ID: 21941579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
